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Robotic-assisted laparoscopic 
prostatectomy: the ideal application for 
antegrade nerve-sparing prostatectomy
“The advent of the da Vinci operating system has changed the 
current urological practice for prostate cancer…”
A total of 217,730 cases of prostate can-
cer are diagnosed annually in the USA [1]. 
Most patients are diagnosed with the 
tumor localized within the prostate gland 
and are potentially curable by surgery. In 
these cases radical prostatectomy (RP) is 
considered the treatment of choice, involv-
ing complete prostate gland removal, with 
high recurrence-free and cancer-specific 
survival rates [2,3]. 
For RP, the usual approach was the ret-
rograde technique described by Walsh and 
Donker in the early 1980s [4]. Reported 
advantages of this approach were the possi-
bility to achieving optimal exposure of the 
prostate and periprostatic tissues, includ-
ing the neurovascular bundles. Possible 
disadvantages included the dissection 
of the dorsal vein complex in the initial 
phase of the operation, and the isolation 
of the apex and of the membranous ure-
thra when the prostate is still attached to 
the periprostatic tissues, making it impos-
sible to put sufficient traction on the pros-
tate to adequately to lengthen the spared 
functional urethra. 
Nevertheless, retrograde RP has been 
the most popular and most used tech-
nique in the past 30 years. The antegrade 
approach was originally described by 
Campbell in 1959 [5] and was then pre-
sented again 20 years later by Mittemeyer 
and Cox [6]. In contrast to the Walsh 
retrograde technique, the antegrade 
approach begins with the incision of the 
bladder neck. Then the prostatic base 
and seminal vesicles are isolated and the 
bundles are approached from the base of 
the prostate, where they are thicker and 
further from the prostatic surface to the 
prostatic apex where they are thinner. 
The dorsal vein complex and the apex 
are dissected and the urethra is incised 
as the last steps of the procedure, with the 
prostate otherwise completely mobilized. 
This leads to a lower risk of intraoperative 
bleeding and to an optimal definition of 
the anatomical boundaries of the apex, 
consequently decreasing the possibility 
of positive surgical margins at this site. 
Preliminary data have already demon-
strated that this technique could pro-
vide better visualization and less blood 
loss than the retrograde approach [6]. 
Nevertheless, very few centers adopted 
the antegrade approach, challenging the 
widely accepted retrograde technique 
for the supposed diff iculty of incis-
ing the bladder neck at the right level, 
and for the ‘unconventional’ approach 
to the neurovascular bundles in case of 
nerve-sparing procedures [7]. We have 
systematically used the open antegrade 
retropubic approach since the mid-1980s, 
with over 1500 procedures performed 
in this period. Our recent publications 
confirmed the historical results reported, 
showing that the antegrade RP provides 
optimal cancer control and a low inci-
dence of positive surgical margins even 
in the presence of limited extra capsular 
tumor spread [8,9]. Moreover, with the 
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increasing interest in quality of life, we evaluated the func-
tional results in terms of recovery of continence and potency, 
showing, after a minimum follow-up of 12 months, a 94% rate 
of complete continence and 70% potency rate after bilateral 
nerve-sparing RP [8]. In recent years, the antegrade approach 
was revisited by surgeons involved in minimally invasive surgery 
owing to the advent of laparoscopic RP (LRP). The laparoscopic 
approach perfectly complemented the antegrade approach for 
the technical needs of laparoscopy in general to work in an 
antegrade direction. Several reports demonstrated that LRP 
was associated with advantages such as reducing intraoperative 
blood loss and transfusion requirements, and also involves safe 
and easy catheter removal with a faster return to normal life. 
Complication rates and functional results were similar to those 
reported after open RP [10,11]. Nevertheless, the acceptance and 
diffusion of traditional LRP was limited worldwide primarily 
owing to the technical difficulties inherent in the procedure and 
to the consequent steep learning curve. 
“…approximately 5000 robotic procedures have 
been performed in Italy in 2010, with most 
consisting of robot-assisted laparoscopic radical 
prostatectomy, with a documented 30–40% yearly 
increase in the number of robotic procedures in the 
last few years.”
The advent of the da Vinci operating system (Intuitive 
Surgical, Inc., CA, USA) has changed current urological practice 
for prostate cancer in many countries owing to 3D imaging dur-
ing the procedure. 3D imaging creates the possibility of having 
complete control of the three operating arms plus the camera 
by one surgeon from the console, and the possibility to filter 
and translate the surgeon’s hand movements into more precise 
micromovements of the instruments with seven degrees of free-
dom. Indeed, robot-assisted LRP (RALP) had a rapid and wide 
diffusion across the world, and as for LRP, the antegrade tech-
nique has also become the standard for RALP. Currently, in the 
USA, more than 75% of RPs are performed using the da Vinci 
platform [12]. At present in Italy (data reviewed in January 2011), 
there are 52 Da Vinci Surgical Systems, and of those, six, nine 
and 15 were installed in 2008, 2009 and from January 2010 to 
January 2011, respectively. Approximately 5000 robotic proce-
dures have been performed in Italy in 2010, with most consisting 
of RALPs, with a documented 30–40% yearly increase in the 
number of robotic procedures in the last few years [Minervini A; 
Unpublished Data]. The initial speed of this change was attributed 
to ‘marketing interests of the robot company’ and this cannot 
be neglected; however, this cannot be sufficient to justify the 
success of RALP in displacing open retrograde RP and LRP as 
the standard surgical approaches for clinically localized prostate 
cancer, both for surgeons who have the facilities of the robotic 
unit in their centers, and for most patients. 
However, every proposed minimally invasive therapy should 
be compared and confirmed to be at least equal in their onco-
logical and functional efficacy and safety to that of open 
retrograde RP, and only after this step can it be considered a 
viable alternative and eventually become the standard method. 
Unfortunately, there is a lack of standardized assessment and 
outcome reporting in RALP, and this also applies and was 
probably more evident when analysing older open retrograde 
RP studies that did not use validated questionnaires for conti-
nence and erectile dysfunction. Therefore, in reports of prostate 
cancer, when evaluating surgical, functional and oncological 
results of open retrograde RP and RALP, there is the real risk 
of not comparing ‘apples with apples’. There is a clear need for 
randomized controlled trials to be organized that confirm the 
superiority of one approach over another; however, at present, 
it seems extremely difficult to perform such a study owing to 
the difficulties of most skilled robotic surgeons to randomized 
patients with clinically localized prostate cancer in the open 
prostatectomy arm of the treatment, as well as the reluctance 
of most patients that decided to go for a robotic procedure to 
be operated by an open approach.
Available studies demonstrated that in experienced hands, patients 
undergoing RALP fare very well, with a shorter hospital stay, less 
blood loss, and faster recovery of potency and continence [13,14]. 
The oncological outcomes of RALP are still presented using 
surrogate end points such as the positive surgical margin (PSM) 
rate. Using these oncological end points, RALP has been shown 
to be equivalent to open retropubic prostatectomy with a trend 
toward lower PSM rates in the RALP group [15,16]. Smith et al. 
evaluated the incidence and location of PSM between 200 open 
retrograde RPs and 200 RALPs, and concluded that the use of the 
robot reduces PSM rates as compared with open RP, especially in 
low- and intermediate-risk patients, and in those treated with the 
nerve-sparing technique [17]. 
“The present impressive increase in robotic surgical 
volume … initially attributed to ‘marketing 
interests of the robot company’ is truly and mainly 
owing to the use of an effective approach, the 
antegrade prostatectomy, coupled with the 
technical advantages of robotic surgery…”
Significant data supporting the oncological effectiveness 
of RALP have also been obtained by two recent studies with 
a long follow-up that considered the more reliable biochemi-
cal disease-free survival (bDFS) rate as the oncological end 
point [18,19]. Indeed, Menon et al. evaluated a series of 1384 con-
secutive patients who had RALP, and with a median follow-up of 
5 years. The authors reported 189 biochemical recurrences, with 
a reported actuarial bDFS rate at 3, 5 and 7 years of 90.6, 86.6 
and 81.0%, respectively. In a multivariate ana lysis, the strongest 
predictors of bDFS were pathological Gleason grade 8–10 (hazard 
ratio: 5.37; p < 0.0001) and pathological stage T3b/T4 (hazard 
ratio: 2.71; p < 0.0001) [18]. 
Similar results were also reported by Mottrie et al. in a recent 
review, where they provided data from a subgroup of 184 patients 
with a minimum follow-up of 60 months [19]. Specifically, the 3-, 
5- and 7-year bDFS rates were 91, 84 and 81%, respectively. Such 
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long-term oncological data can be considered as confirmation of 
the oncological safety predicted by previous reports that evaluated 
the PSM rate. 
In conclusion, the present impressive increase in robotic surgical 
volume in many countries, initially attributed to ‘marketing inter-
ests of the robot company’ is truly and mainly owing to the use of 
an effective approach, the antegrade prostatectomy, coupled with 
the technical advantages of robotic surgery, and to the consequent 
documented optimal surgical, oncological and functional results 
obtained. The era of robotic surgery for the treatment of prostate 
cancer has come and is here to stay, and a decrease in the price 
of robotic surgery, making this device more affordable and more 
accessible, would surely contribute to widen the indications for 
RALP and to convincing those sceptical of RALP, improve the 
worldwide diffusion of robotic surgery.
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